These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 26056125

  • 1. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
    Chung ES, Miller L, Patel AN, Anderson RD, Mendelsohn FO, Traverse J, Silver KH, Shin J, Ewald G, Farr MJ, Anwaruddin S, Plat F, Fisher SJ, AuWerter AT, Pastore JM, Aras R, Penn MS.
    Eur Heart J; 2015 Sep 01; 36(33):2228-38. PubMed ID: 26056125
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial.
    Bauersachs J, Solomon SD, Anker SD, Antorrena-Miranda I, Batkai S, Viereck J, Rump S, Filippatos G, Granzer U, Ponikowski P, de Boer RA, Vardeny O, Hauke W, Thum T.
    Eur J Heart Fail; 2024 Mar 01; 26(3):674-682. PubMed ID: 38269451
    [Abstract] [Full Text] [Related]

  • 3. Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial.
    Hammond HK, Penny WF, Traverse JH, Henry TD, Watkins MW, Yancy CW, Sweis RN, Adler ED, Patel AN, Murray DR, Ross RS, Bhargava V, Maisel A, Barnard DD, Lai NC, Dalton ND, Lee ML, Narayan SM, Blanchard DG, Gao MH.
    JAMA Cardiol; 2016 May 01; 1(2):163-71. PubMed ID: 27437887
    [Abstract] [Full Text] [Related]

  • 4. Interatrial shunt therapy in advanced heart failure: Outcomes from the open-label cohort of the RELIEVE-HF trial.
    Rodés-Cabau J, Lindenfeld J, Abraham WT, Zile MR, Kar S, Bayés-Genís A, Eigler N, Holcomb R, Núñez J, Lee E, Perl ML, Moravsky G, Pfeiffer M, Boehmer J, Gorcsan J, Bax JJ, Anker S, Stone GW.
    Eur J Heart Fail; 2024 Apr 01; 26(4):1078-1089. PubMed ID: 38561314
    [Abstract] [Full Text] [Related]

  • 5. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.
    Bartunek J, Terzic A, Davison BA, Filippatos GS, Radovanovic S, Beleslin B, Merkely B, Musialek P, Wojakowski W, Andreka P, Horvath IG, Katz A, Dolatabadi D, El Nakadi B, Arandjelovic A, Edes I, Seferovic PM, Obradovic S, Vanderheyden M, Jagic N, Petrov I, Atar S, Halabi M, Gelev VL, Shochat MK, Kasprzak JD, Sanz-Ruiz R, Heyndrickx GR, Nyolczas N, Legrand V, Guédès A, Heyse A, Moccetti T, Fernandez-Aviles F, Jimenez-Quevedo P, Bayes-Genis A, Hernandez-Garcia JM, Ribichini F, Gruchala M, Waldman SA, Teerlink JR, Gersh BJ, Povsic TJ, Henry TD, Metra M, Hajjar RJ, Tendera M, Behfar A, Alexandre B, Seron A, Stough WG, Sherman W, Cotter G, Wijns W, CHART Program.
    Eur Heart J; 2017 Mar 01; 38(9):648-660. PubMed ID: 28025189
    [Abstract] [Full Text] [Related]

  • 6. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
    Tardif JC, O'Meara E, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K, SHIFT Investigators.
    Eur Heart J; 2011 Oct 01; 32(20):2507-15. PubMed ID: 21875858
    [Abstract] [Full Text] [Related]

  • 7. Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial.
    Taylor DA, Perin EC, Willerson JT, Zierold C, Resende M, Carlson M, Nestor B, Wise E, Orozco A, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Traverse JH, Cooke JP, Schutt RC, Bhatnagar A, Grant MB, Lai D, Johnstone BH, Sayre SL, Moyé L, Ebert RF, Bolli R, Simari RD, Cogle CR, Cardiovascular Cell Therapy Research Network (CCTRN).
    Cell Transplant; 2016 Oct 01; 25(9):1675-1687. PubMed ID: 26590374
    [Abstract] [Full Text] [Related]

  • 8. Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED-HF.
    Halliday BP, Owen R, Gregson J, S Vassiliou V, Chen X, Wage R, Lota AS, Khalique Z, Tayal U, Hammersley DJ, Jones RE, Baksi AJ, Cowie MR, Cleland JGF, Pennell DJ, Prasad SK.
    Eur J Heart Fail; 2021 Feb 01; 23(2):293-301. PubMed ID: 33225554
    [Abstract] [Full Text] [Related]

  • 9. Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure.
    Borow KM, Yaroshinsky A, Greenberg B, Perin EC.
    Circ Res; 2019 Jul 19; 125(3):265-281. PubMed ID: 31318648
    [Abstract] [Full Text] [Related]

  • 10. Dose-response relationship of MSCs as living Bio-drugs in HFrEF patients: a systematic review and meta-analysis of RCTs.
    Ahmed ZT, Zain Al-Abeden MS, Al Abdin MG, Muqresh MA, Al Jowf GI, Eijssen LMT, Haider KH.
    Stem Cell Res Ther; 2024 Jun 13; 15(1):165. PubMed ID: 38867306
    [Abstract] [Full Text] [Related]

  • 11. HF Etiology and cardiac contractility modulation therapy.
    Davtyan K, Chugunov I, Topchyan A, Mareev Y, Mironova N, Rimskaya E, Golitsyn S, Mikhaylov E, Lebedev D, Vander M, Lyasnikova E, Sitnikova M, Minjia K, Glembo S, Sukhorukov O.
    BMC Cardiovasc Disord; 2024 May 29; 24(1):279. PubMed ID: 38811946
    [Abstract] [Full Text] [Related]

  • 12. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.
    Butler J, Abildstrøm SZ, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, Shah SJ, Verma S, Abhayaratna WP, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Núñez J, Perna E, Schou M, Senni M, van der Meer P, von Lewinski D, Wolf D, Altschul RL, Rasmussen S, Kosiborod MN.
    J Am Coll Cardiol; 2023 Nov 28; 82(22):2087-2096. PubMed ID: 37993201
    [Abstract] [Full Text] [Related]

  • 13. Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: Rationale, Design and Lead-in Phase Results of the REBALANCE-HF Trial.
    Fudim M, Litwin SE, Borlaug BA, Mohan RC, Price MJ, Fail P, Zirakashvili T, Shaburishvili T, Goyal P, Hummel SL, Patel RB, Reddy VY, Burkhoff D, Patel MR, Somo SI, Shah SJ.
    J Card Fail; 2024 Jul 28; 30(7):877-889. PubMed ID: 38211934
    [Abstract] [Full Text] [Related]

  • 14. Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial.
    Tian Z, Li L, Li X, Wang J, Zhang Q, Li Z, Peng D, Yang P, Ma W, Wang F, Jin W, Cheng X, Sun J, Fu Y, Lyu C, Zhang S.
    JAMA Cardiol; 2023 Oct 01; 8(10):957-965. PubMed ID: 37639259
    [Abstract] [Full Text] [Related]

  • 15. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
    Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, Smith A, Heemelaar JC, Brahmbhatt P, Ho JS, Sama S, Svoboda J, Neuberg DS, Abramson JS, Hochberg EP, Barnes JA, Armand P, Jacobsen ED, Jacobson CA, Kim AI, Soumerai JD, Han Y, Friedman RS, Lacasce AS, Ky B, Landsburg D, Nasta S, Kwong RY, Jerosch-Herold M, Redd RA, Hua L, Januzzi JL, Asnani A, Mousavi N, Scherrer-Crosbie M.
    JAMA; 2023 Aug 08; 330(6):528-536. PubMed ID: 37552303
    [Abstract] [Full Text] [Related]

  • 16. Long-term outcomes and reverse remodelling in recently diagnosed unexplained left ventricular systolic dysfunction.
    Kuchynka P, Podzimkova J, Marek J, Danek BA, Vitkova I, Kreidlova M, Roblova L, Kovarnik T, Simek S, Horak J, Habasko J, Linhart A, Palecek T.
    ESC Heart Fail; 2024 Apr 08; 11(2):859-870. PubMed ID: 38204216
    [Abstract] [Full Text] [Related]

  • 17. Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial.
    Balligand JL, Brito D, Brosteanu O, Casadei B, Depoix C, Edelmann F, Ferreira V, Filippatos G, Gerber B, Gruson D, Hasenclever D, Hellenkamp K, Ikonomidis I, Krakowiak B, Lhommel R, Mahmod M, Neubauer S, Persu A, Piechnik S, Pieske B, Pieske-Kraigher E, Pinto F, Ponikowski P, Senni M, Trochu JN, Van Overstraeten N, Wachter R, Pouleur AC.
    JAMA Cardiol; 2023 Nov 01; 8(11):1031-1040. PubMed ID: 37728907
    [Abstract] [Full Text] [Related]

  • 18. Non-pharmacologic autonomic neuromodulation for treatment of heart failure: A systematic review and meta-analysis of randomized controlled trials.
    Ahmed M, Nudy M, Bussa R, Weigel F, Naccarelli G, Maheshwari A.
    Trends Cardiovasc Med; 2024 Feb 01; 34(2):101-107. PubMed ID: 36202286
    [Abstract] [Full Text] [Related]

  • 19. Improvement in left atrial strain following ferric carboxymaltose in heart failure: an analysis of the Myocardial-IRON trial.
    Santas E, Del Canto I, Cardells I, Miñana G, Llàcer P, Almenar L, Fácila L, Maceira AM, Sanchis J, Núñez J, Myocardial‐IRON Investigators.
    ESC Heart Fail; 2024 Apr 01; 11(2):1258-1262. PubMed ID: 38115745
    [Abstract] [Full Text] [Related]

  • 20. Cardiac shockwave therapy in addition to coronary bypass surgery improves myocardial function in ischaemic heart failure: the CAST-HF trial.
    Holfeld J, Nägele F, Pölzl L, Engler C, Graber M, Hirsch J, Schmidt S, Mayr A, Troger F, Pamminger M, Theurl M, Schreinlechner M, Sappler N, Ruttmann-Ulmer E, Schaden W, Cooke JP, Ulmer H, Bauer A, Gollmann-Tepeköylü C, Grimm M.
    Eur Heart J; 2024 Jun 20. PubMed ID: 38898573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.